RAD 140 For Sale
The Origin of This Promising Research SARM
In 2007, Radius Health filed a patent describing the research compound that would later be called RAD 140, or Testolone. Their goal was to develop a drug that could strengthen muscles and bones without many of the unwanted side effects of traditional anabolic compounds. Researchers saw potential in using it to treat muscle wasting diseases, osteoporosis and even prevent breast cancer recurrence.
This novel selective androgen receptor modulator (SARM) aimed to deliver targeted benefits like:
- Increased lean muscle mass
- Enhanced strength
- Accelerated healing from injuries
- Greater bone density
Without disrupting mental well-being or causing damage to the heart, liver, or prostate like anabolic steroids sometimes do.
RAD 140 Chemical Structure
The molecular structure of Testolone gives clues into how this experimental therapy exerts such potent muscle-building effects. Testolone features:
- A distinct bicyclic core structure made up of a benzonitrile ring bonded to a 1,3,4-oxadiazole ring
- A cyano-substituted phenyl group linking the two rings
- A cyano functional group and hydroxy group that allow it to bind tightly to androgen receptors
Researchers believe these structural characteristics drive RAD 140’s ability to trigger muscle and bone cell growth selectively.
Behind The Scenes – Effects and Results
When Testolone reaches muscle and bone cells, it binds to androgen receptors on them. This connection causes a change in the receptor’s shape that allows it to travel into the nucleus of the cell.
Once inside the nucleus, these stimulated androgen receptors activate specific genes that switch on muscle and bone growth processes. This selective gene activation is what enables RAD 140 to have the potential for building lean muscle and boosting performance without over activating genes that trigger unwanted side effects.
SARMs Research Studies
Over the years, RAD 140 has gone through pre-clinical research and phase 1 clinical trials – let’s take a more in-depth look at a couple of them.
One study conducted in 2010, characterized the stability, bioavailability, receptor binding affinity, and functional activity of the selective androgen receptor modulator (SARM) RAD140 in preclinical models.
Here are some of the key findings:
- RAD140 demonstrated high stability in rat, monkey, and human microsomes and good oral bioavailability in animal models
- It exhibited a potent binding affinity for the androgen receptor, almost 4 times higher than testosterone
- RAD140 showed strong functional androgen agonist activity in a bone cell assay
- In castrated male rats, RAD140 increased muscle weight at doses as low as 0.03 mg/kg. It showed reduced stimulatory effects on the prostate and seminal vesicles compared to testosterone.
- In intact male rats with some endogenous testosterone, very high doses of RAD140 were required to stimulate prostate growth, demonstrating tissue selectivity.
- In monkeys, RAD140 increased body weight by >10% and lean mass in 28 days at just 0.1 mg/kg. It lowered lipids and showed minimal liver enzyme elevation even at very high doses.
- In summary, this pre-clinical data shows RAD140 meets the criteria of a SARM. It stimulates muscle and bone more potently than reproductive tissues, demonstrating potency and selectivity. RAD140 was well-tolerated and displayed a favorable profile in advancing in human clinical testing for cancer cachexia.
Interestingly, RAD 140 has also been tested on breast cancer patients.
This first-in-human phase 1 trial evaluated the new selective androgen receptor modulator (SARM) RAD140 in 22 heavily pretreated women with metastatic ER+/HER2- breast cancer. RAD140 was given orally at escalating doses from 50-150 mg daily. The goals were to determine the maximum tolerated dose (MTD), safety, side effects, pharmacokinetics, and early signs of effectiveness.
The most common side effects were elevated liver enzymes, vomiting, dehydration, decreased appetite/weight, and electrolyte imbalances. RAD140 exhibited a half-life of 44.7 hours, supporting once-daily dosing. 18% of patients achieved clinical benefit at 24 weeks.
Changes in sex hormone binding globulin and prostate-specific antigen indicated RAD140 successfully engaged the androgen receptor. Tumor biopsies also showed androgen receptor pathway activation.
In summary, this first-in-human trial showed RAD140 has an acceptable safety profile in metastatic breast cancer patients at MTD of 100 mg/day with signals of androgen receptor engagement and potential anti tumor activity warranting further studies.
Quality Research Products For Sale
If your research could benefit from a premium source of RAD140, look no further. As a leading SARMs supplier dedicated to purity and potency, we:
- Rigorously test every batch to verify its authenticity and quality
- Produce research products under strict quality control standards
- Price competitively and ship quickly without compromising on service
Our manufacturing process prioritizes quality and performance – our goal is to build trust and meet the needs of researchers first and foremost. We take pride in paying close attention to the details that set quality SARMs apart:
Before a single drop leaves our lab, we use cutting-edge techniques like HPLC, and mass spec testing to confirm the purity and identity of RAD140. You can see the results for yourself because we make all lab reports available to our customers.
Finding the optimal balance between solubility and convenience motivated us to offer RAD140 as a 15 mg/ml solution. This allows for precision without requiring unsafe solvents.
When your research calls for a pure, high-quality compound, we step up to deliver. Our world-class customer service team is always ready to help with any questions before you place an order.
|Also Known As
|Store in a cool dry place
|The products we offer are intended for laboratory research use only.
Please read our Terms & Conditions prior to ordering.
The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. If you choose to buy products from us, you agree that they’re for laboratory research use, and not for human consumption.
Miller CP, Shomali M, Lyttle CR, O’Dea LS, Herendeen H, Gallacher K, Paquin D, Compton DR, Sahoo B, Kerrigan SA, Burge MS, Nickels M, Green JL, Katzenellenbogen JA, Tchesnokov A, Hattersley G. Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140. ACS Med Chem Lett. 2010 Dec 2;2(2):124-9. doi: 10.1021/ml1002508. PMID: 24900290; PMCID: PMC4018048.
LoRusso P, Hamilton E, Ma C, Vidula N, Bagley RG, Troy S, Annett M, Yu Z, Conlan MG, Weise A. A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer. Clin Breast Cancer. 2022 Jan;22(1):67-77. doi: 10.1016/j.clbc.2021.08.003. Epub 2021 Aug 20. PMID: 34565686.